Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LE-DT in metastatic castrate resistant prostate cancer
NCT01188408Phase 2Withdrawn
- Sponsor
- Insys Therapeutics
- Start
- Jun 2010
- Primary completion
- Sep 2011
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of liposome entrapped docetaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Insys Therapeutics. Planned start Jun 2010; status: withdrawn.
02
Drugs
liposome entrapped docetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01188408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01188408.